Plain-English translation of NCT05950945 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a drug called (T-DXd) for people with advanced breast cancer that cannot be surgically removed and has spread to other parts of the body. The cancer in this trial has low levels or no HER2 protein, which makes it different from other types of breast cancer. Researchers want to see how long this medication can help keep the cancer from getting worse.
Many people with advanced breast cancer that has low HER2 levels have limited treatment options after their first or second round of therapy stops working. This trial exists to see if this new medication can offer hope and extend the time before patients need different treatments.
You likely qualify if…
You likely don't qualify if…
Participants will receive the medication as an intravenous infusion on a regular treatment schedule. You will have frequent visits to the clinic for infusions, blood tests, and imaging scans to monitor how your cancer is responding to treatment. The study will track how long you are able to benefit from this medication before needing a different treatment, and researchers will monitor you carefully for any side effects. You will also need to provide a tissue sample from your tumor to confirm your cancer type.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States